Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens
ثبت نشده
چکیده
Tel Aviv, Israel, 25 December 2012: Micromedic (TASE: MCTC), a development and commercialization company working to create value through a cluster of cancer diagnostics companies, has announced that positive interim results have been obtained from a clinical trial conducted to assess the capability of Zetiq’s (wholly owned subsidiary of Micromedic) CellDetect technology, to detect bladder cancer cells in urine specimens.
منابع مشابه
Evaluation of Sensitivity and Specificity of Urine Survivin As A New Molecular Marker in Diagnosis of Bladder Tumors
Bladder cancer is one of the most common forms of cancers in the world. The current gold standards for itsdiagnosis are cystoscopy and urine cytology. Cystoscopy, a naked eye assessment of the bladder, is invasive, uncomfortable and costly with a great deal of personal variability in its results; while urine cytology has high specificity but low sensitivity, particularly for low-grade les...
متن کاملمقایسه حساسیت و ویژگی سیتولوژی و اندازه گیری فعالیت تلومراز در ادرار به روش Trap Assay جهت تشخیص سرطان مثانه
Introduction & Objective : Telomerase is a reverse transcriptase enzyme that is required in immortalized cancer cells. Early detection of telomerase activity in tumors particularly in bladder cancer is promising. The aim of this study was to compare specificity and sensitivity between cytology and telomerase activity in diagnosis of bladder cancer. Materials & Methods : This study was a case...
متن کاملEvaluation of in vitro Effect of Pyocyanine Pigment on Interleukin-2 Secretion from Peripheral Blood Mononuclear Cells in Cancer Patients
Background and Objective: The pyocyanine pigment in Pseudomonas aeruginosa stimulates blood cells to secrete IL-2. IL-2 cytokine is an activator of cytotoxic T cells and natural killer cells. These cells destroy the target cells of patients with cancer. This study aimed to evaluate the effects of pyocyanine on the IL-2 secretion from peripheral blood mononuclear cells (PBMCs) in patients with b...
متن کاملEvaluating the Expression of Oct4 as a Prognostic Tumor Marker in Bladder Cancer
Objective(s)The key transcriptional regulator Oct4 is one of the self-renewal and differentiation-related factors in cancer stem cells, where it maintains "stemness" state. Cancer stem cells have been identified in a variety of solid malignancies. They are a small population of tumor cells with stem cell characteristics, which are a likely cause of relapse in cancer patients. Due to high incide...
متن کاملتشخیص کارسینوم سلول ترانزیشنال مثانه: hTERT در مقایسه با سیتولوژی ادرار
Background: Transitional Cell Carcinoma (TCC) of bladder is the second most common urogenital malignancy and because of its high rate of recurrence (two third of tumors recur) vigilant surveillance is necessary. There have been a lot of efforts to find a proper biomarker for detecting urothelial cancers because available methods are expensive and invasive (like cystoscopy) or have a low degree ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2012